Anton P Porsteinsson
Overview
Explore the profile of Anton P Porsteinsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
2858
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lanctot K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, et al.
Am J Geriatr Psychiatry
. 2023 Jun;
31(12):1077-1087.
PMID: 37385898
Objective: The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) found that methylphenidate was effective in treating apathy with a small-to-medium effect size but showed heterogeneity in response. We assessed...
12.
Lanctot K, Chen C, Mah E, Kiss A, Li A, Shade D, et al.
Int Psychogeriatr
. 2023 Apr;
35(11):664-672.
PMID: 37066690
Background: This paper used data from the Apathy in Dementia Methylphenidate Trial 2 (NCT02346201) to conduct a planned cost consequence analysis to investigate whether treatment of apathy with methylphenidate is...
13.
Lee D, Clark E, Antonsdottir I, Porsteinsson A
Expert Opin Pharmacother
. 2023 Mar;
24(6):691-703.
PMID: 36958727
Introduction: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for patients and their care partners. Agitation is a common and distressing NPS, without safe and effective...
14.
Turnbull A, Anthony M, Tadin D, Porsteinsson A, Heffner K, Lin F
Cortex
. 2023 Jan;
159:131-141.
PMID: 36623419
Background: Neuropsychiatric symptoms (NPS) in mild cognitive impairment (MCI) cause distress to patients and caregivers, and accelerate progression to dementia. Transcranial direct current stimulation (tDCS) is a promising non-invasive treatment...
15.
Porsteinsson A, Rangaraju S, Spires-Jones T, OBanion M
Eur J Neurosci
. 2022 Nov;
56(9):5337-5341.
PMID: 36324230
No abstract available.
16.
Spira A, Zipunnikov V, Raman R, Choi J, Di J, Bai J, et al.
Sleep Adv
. 2021 Oct;
2(1):zpab015.
PMID: 34661109
Study Objectives: To examine in a subsample at the screening phase of a clinical trial of a β-amyloid (Aβ) antibody whether disturbed sleep and altered 24-hour rest/activity rhythms (RARs) may...
17.
Mintzer J, Lanctot K, Scherer R, Rosenberg P, Herrmann N, van Dyck C, et al.
JAMA Neurol
. 2021 Sep;
78(11):1324-1332.
PMID: 34570180
Importance: Apathy, characterized by diminished will or initiative and one of the most prevalent neuropsychiatric symptoms in individuals with Alzheimer disease, is associated with significant caregiver burden, excess disability, increased...
18.
Porsteinsson A, Clark E
Int Psychogeriatr
. 2021 Mar;
33(3):199-200.
PMID: 33781358
No abstract available.
19.
Abushakra S, Porsteinsson A, Sabbagh M, Bracoud L, Schaerer J, Power A, et al.
Alzheimers Dement (N Y)
. 2020 Dec;
6(1):e12117.
PMID: 33304988
Introduction: Hippocampal volume (HV) and cortical thickness are commonly used imaging biomarkers in Alzheimer's disease (AD) trials, and may have utility as selection criteria for enrichment strategies. Atrophy rates of...
20.
Lanctot K, Scherer R, Li A, Vieira D, Coulibaly H, Rosenberg P, et al.
Am J Geriatr Psychiatry
. 2020 Jun;
29(1):81-89.
PMID: 32565008
Background: Diagnostic criteria for apathy have been published but have yet to be evaluated in the context of clinical trials. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) operationalized...